Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DS BIOPHARMA LIMITED

Home Clinical Trial Sponsors and OrganizationsDS BIOPHARMA LIMITED

DS BIOPHARMA LIMITED

Trintech Building, Dublin, Ireland

Also known as:

ds biopharma

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

9

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

5

55.6%

Phase 1

4

44.4%

Trial Status Distribution

Active, not recruiting

3

33.3%

Completed

5

55.6%

Terminated

1

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Sep 2019219 participants

A Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic Pruritus

Active, not recruiting

Jun 2018110 participants

A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assessthe Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic Pruritus

Active, not recruiting

Nov 2017110 participants

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Jan 2017321 participants

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Dec 2016327 participants

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Oct 20155 participants

A Study of DGLA Cream in early childhood patients with atopic dermatitis - inflammatory skin disease.

Active, not recruiting

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

Jul 201557 participants

Page 1 of 2

Approvals

No approval data available

News

India Releases Draft 2026 Pharmaceutical Patent Examination Guidelines Rebuilding Examiner Toolkit Around a Decade of Case Law

- India's CGPDTM published Draft Guidelines for examination of pharmaceutical patent applications on September 4, 2026, inviting public comments before finalisation. - The draft rebuilds the examiner's framework around roughly two dozen judicial decisions, including the 2013 Novartis ruling and Delhi High Court judgments from 2024–2026. - Section 3(d) efficacy analysis is reinforced as a data-driven inquiry, with bioavailability clarified as a pharmacokinetic parameter rather than a direct measure of therapeutic efficacy. - New structured tests for novelty ("Seven Stambha") and inventive step, plus dedicated treatment of Markush and product-by-process claims, signal stricter prosecution standards.

On this page

Overview
Clinical Trials9
Approvals
News1

Back to Organizations